In addition, FASN enhances the production of membrane RTKs, including EGFR, ERBB2, and hepatocyte growth factor receptor/c-MET, in breast, ovarian, and prostate cancers, as well as non-Hodgkin lymphoma (Menendez et al., 2004a; Uddin et al., 2010). Here, MET is linked to non-Hodgkin lymphoma.